A Phase 4 interventional study of Baricitinib and TNF Inhibitor in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 261 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 9 in phase 4, and was the 14th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,659 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 4, and was the 28th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have at least one of the following characteristics:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 milligrams (mg) of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the data monitoring committee (DMC) recommended early termination. Those with inadequate response at 1-year after start of treatment with baricitinib 2mg could receive rescue treatment with baricitinib 4mg.
Drug: Baricitinib
Participants received 4 mg of baricitinib once daily until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.
Drug: Baricitinib
Participants received a TNF inhibitor (adalimumab or etanercept) administered according to approved local labeling until the planned number of adjudicated primary endpoint events occurred or until the DMC recommended early termination.
Drug: TNF Inhibitor
Administered orally.
Also known as: LY3009104
Administered subcutaneously.
Also known as: Etanercept, Adalimumab
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor]
Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
Time frame: From the first dose of study treatment up to 30 days after the last dose or the last study visit, whichever occurs first (approximately up to 6.1 years for JAJA and 5.3 years for JAJD participants)
Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor
Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. * TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. * Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.
Time frame: From the date of first dose of study drug up to the last dose (approximately up to 6.1 years)
| Milestone | Baricitinib 2mg | Baricitinib 4mg | Tumor Necrosis Factor (TNF) Inhibitor |
|---|---|---|---|
| Started | 886 | 886 | 887 |
| Safety analysis set | 879 | 881 | 880 |
| Pooled analysis set | 1219 | 1214 | 1207 |
| Completed | 433 | 428 | 415 |
| Not completed | 453 | 458 | 472 |
| Withdrew: Adverse event | 112 | 120 | 110 |
| Withdrew: Death | 16 | 32 | 23 |
| Withdrew: Protocol deviation | 10 | 16 | 15 |
| Withdrew: Withdrawal by subject | 124 | 109 | 130 |
| Withdrew: Physician decision | 16 | 13 | 19 |
| Withdrew: Lack of efficacy | 55 | 37 | 46 |
| Withdrew: Pregnancy | 0 | 2 | 3 |
| Withdrew: Russia sites closed due to operational limitations & participants unable to attend their final visit | 53 | 59 | 59 |
| Withdrew: Site terminated by sponsor | 1 | 1 | 3 |
| Withdrew: Lost to follow-up | 40 | 37 | 33 |
| Withdrew: Other | 26 | 32 | 31 |
Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first event of VTE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/Body Mass Index (BMI) combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor |
|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first ATE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first MACE was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first malignancy (excluding NMSC) was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Malignancy (Excluding Nonmelanoma Skin Cancer [NMSC]) [Combined and Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first opportunistic infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Opportunistic Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time from first dose of study treatment to first serious infection was evaluated using hazard ratio as the measure of treatment effect, estimated from Cox proportional hazards regression model. The analysis was based on pooled data from studies JAJA (NCT03915964) and JAJD (NCT04086745) and was stratified by study, with treatment group and randomization stratification factors (VTE history, age/BMI combination, prior inadequate response or intolerance to a TNF inhibitor, and geographic region) as explanatory variables.
| Days | Baricitinib 2mg | Baricitinib 4mg | Baricitinib 2/4 mg | TNF Inhibitor |
|---|---|---|---|---|
| Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Serious Infection [Combined and Individual Baricitinib Dose Versus TNF Inhibitor] | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Duration of exposure was calculated as: * Baricitinib 2mg exposure = date of last baricitinib 2mg treatment - date of first baricitinib 2mg dose + 1. For participants who were rescued from baricitinib 2 mg to 4 mg, their drug exposure after rescue was censored and not counted as exposure to baricitinib 2mg. * Baricitinib 4mg exposure = date of last baricitinib 4mg treatment - date of first baricitinib 4mg dose + 1. * TNF inhibitor exposure = date of last TNFi (adalimumab or etanercept) - date of first TNFi dose (adalimumab or etanercept) + 1, regardless of treatment cycling from adalimumab to etanercept or vice versa. * Total baricitinib exposure (2/4 mg) = date of last baricitinib (2mg or 4mg) treatment - date of first baricitinib (2mg or 4mg) dose + 1, regardless of rescue from baricitinib 2mg to baricitinib 4mg. Patient-years is calculated as sum of duration of exposure in days for all patients in dosing regimen divided by 365.25.
| patient-years | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Baricitinib 2/4 mg |
|---|---|---|---|---|
| Total Duration of Treatment Exposure for Combined Baricitinib Dose, Individual Baricitinib Dose and TNF Inhibitor | 2164.3 | 3252.7 | 3158.1 | 6404.8 |
Collected over From the time of the informed consent signature up to the last study visit (approximately up to 6.1 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baricitinib 2mg | 16/886 (1.8%) | 259/879 (29.5%) | 498/879 (56.7%) |
| Baricitinib 4mg | 32/886 (3.6%) | 276/881 (31.3%) | 538/881 (61.1%) |
| TNF Inhibitor | 23/887 (2.6%) | 259/880 (29.4%) | 475/880 (54%) |
| Event | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 18/879 | 23/881 | 11/880 |
| Covid-19 pneumoniaInfections and infestations | 22/879 | 20/881 | 12/880 |
| Covid-19Infections and infestations | 15/879 | 18/881 | 10/880 |
| PneumoniaInfections and infestations | 11/879 | 18/881 | 14/880 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/879 | 15/881 | 6/880 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/194 | 1/179 | 2/178 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/194 | 2/179 | 0/178 |
| Deep vein thrombosisVascular disorders | 9/879 | 9/881 | 4/880 |
| Acute myocardial infarctionCardiac disorders | 4/879 | 9/881 | 3/880 |
| Atrial fibrillationCardiac disorders | 6/879 | 7/881 | 8/880 |
| Event | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor |
|---|---|---|---|
| Covid-19Infections and infestations | 183/879 | 205/881 | 171/880 |
| NasopharyngitisInfections and infestations | 102/879 | 122/881 | 115/880 |
| Urinary tract infectionInfections and infestations | 99/879 | 100/881 | 67/880 |
| Upper respiratory tract infectionInfections and infestations | 86/879 | 92/881 | 77/880 |
| HypertensionVascular disorders | 71/879 | 88/881 | 74/880 |
| BronchitisInfections and infestations | 62/879 | 84/881 | 53/880 |
| Herpes zosterInfections and infestations | 48/879 | 63/881 | 21/880 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 55/879 | 55/881 | 62/880 |
| HeadacheNervous system disorders | 46/879 | 57/881 | 41/880 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 37/879 | 52/881 | 42/880 |
All participants from the safety analysis set.
| Age, Continuous(years) | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Total |
|---|---|---|---|---|
| Mean | 60.10 ± 9.87 | 59.60 ± 9.86 | 60.50 ± 10.24 | 60.10 ± 9.99 |
| Sex: Female, Male(Participants) | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Total |
|---|---|---|---|---|
| Female | 685 | 702 | 702 | 2089 |
| Male | 194 | 179 | 178 | 551 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Total |
|---|---|---|---|---|
| Hispanic or Latino | 85 | 74 | 76 | 235 |
| Not Hispanic or Latino | 730 | 728 | 724 | 2182 |
| Unknown or Not Reported | 64 | 79 | 80 | 223 |
| Race (NIH/OMB)(Participants) | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 7 | 5 | 16 |
| Asian | 12 | 20 | 26 | 58 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 3 |
| Black or African American | 39 | 33 | 17 | 89 |
| White | 804 | 802 | 813 | 2419 |
| More than one race | 1 | 2 | 5 | 8 |
| Unknown or Not Reported | 16 | 17 | 14 | 47 |
| Region of Enrollment(Participants) | Baricitinib 2mg | Baricitinib 4mg | TNF Inhibitor | Total |
|---|---|---|---|---|
| Australia | 21 | 15 | 7 | 43 |
| Austria | 3 | 1 | 4 | 8 |
| Belgium | 7 | 9 | 4 | 20 |
| Czechia | 121 | 115 | 109 | 345 |
| Denmark | 1 | 2 | 1 | 4 |
| France | 7 | 4 | 5 | 16 |
| Germany | 17 | 31 | 26 | 74 |
| Greece | 5 | 4 | 8 | 17 |
| Hungary | 34 | 42 | 41 | 117 |
| Israel | 34 | 38 | 25 | 97 |
| Italy | 10 | 6 | 8 | 24 |
| Lithuania | 7 | 4 | 4 | 15 |
| Netherlands | 4 | 5 | 4 | 13 |
| Poland | 151 | 129 | 136 | 416 |
| Romania | 43 | 39 | 35 | 117 |
| Russia | 67 | 75 | 91 | 233 |
| Slovakia | 13 | 18 | 17 | 48 |
| South Africa | 31 | 32 | 40 | 103 |
| Spain | 52 | 61 | 69 | 182 |
| Switzerland | 7 | 7 | 1 | 15 |
| Turkey | 6 | 4 | 5 | 15 |
| United Kingdom | 13 | 17 | 16 | 46 |
| United States | 225 | 223 | 224 | 672 |
Showing the first 100 of 261 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2019 to primary completion in May 2025, 73 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 73 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib